Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin

PLoS One. 2012;7(10):e46923. doi: 10.1371/journal.pone.0046923. Epub 2012 Oct 9.

Abstract

Current evidence suggests that ghrelin, a stomach derived peptide, exerts its orexigenic action through specific modulation of Sirtuin1 (SIRT1)/p53 and AMP-activated protein kinase (AMPK) pathways, which ultimately increase the expression of agouti-related protein (AgRP) and neuropeptide Y (NPY) in the arcuate nucleus of the hypothalamus (ARC). However, there is a paucity of data about the possible action of ghrelin on alternative metabolic pathways at this level. Here, we demonstrate that ghrelin elicits a marked upregulation of the hypothalamic mammalian target of rapamycin (mTOR) signaling pathway. Of note, central inhibition of mTOR signaling with rapamycin decreased ghrelin's orexigenic action and normalized the mRNA expression of AgRP and NPY, as well as their key downstream transcription factors, namely cAMP response-element binding protein (pCREB) and forkhead box O1 (FoxO1, total and phosphorylated). Taken together, these data indicate that, in addition to previous reported mechanisms, ghrelin also promotes feeding through modulation of hypothalamic mTOR pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agouti-Related Protein / metabolism
  • Animals
  • Appetite Stimulants / administration & dosage
  • Appetite Stimulants / pharmacology*
  • Arcuate Nucleus of Hypothalamus / cytology
  • Arcuate Nucleus of Hypothalamus / drug effects
  • Arcuate Nucleus of Hypothalamus / metabolism
  • Arcuate Nucleus of Hypothalamus / physiology
  • Eating / drug effects
  • Feeding Behavior / drug effects
  • Feeding Behavior / physiology
  • Ghrelin / administration & dosage
  • Ghrelin / pharmacology*
  • Hypothalamus / cytology*
  • Hypothalamus / drug effects
  • Hypothalamus / metabolism
  • Hypothalamus / physiology*
  • Male
  • Neuropeptide Y / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects*
  • TOR Serine-Threonine Kinases / metabolism*
  • Time Factors
  • Transcription Factors / metabolism

Substances

  • Agouti-Related Protein
  • Appetite Stimulants
  • Ghrelin
  • Neuropeptide Y
  • Transcription Factors
  • TOR Serine-Threonine Kinases

Grants and funding

The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement n° 281854 - the ObERStress project (ML) and 245009 - the Neurofast project (RN, CD and ML), Xunta de Galicia (ML: 10PXIB208164PR; RN: 2010/14), Junta de Andalucía (MTS: P08-CVI-03788), Instituto de Salud Carlos III (ISCIII) (ML: PS09/01880), MINECO co-funded by the FEDER Program of EU (MTS: BFU2011-25021; RN: RyC-2008-02219 and SAF2009-07049; ML: RyC-2007-00211; CD: BFU2011-29102). LM is a recipient of a fellowship from Fundação para a Ciência e Tecnologia (FCT), Portugal (SFRH/BD/65379/2009). CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.